Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates [Yahoo! Finance]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
In the year-ago quarter, the company posted a loss of $1.11 per share. Insmed generated total revenues of $93.4 million during the quarter, up 18% year over year. Quarterly sales were in line with the Zacks Consensus Estimate. Shares of INSM were down more than 4% on Thursday likely due to the earnings miss. See the Zacks Earnings Calendar to stay ahead of market-making news. Year to date, shares of Insmed have surged 117.1% against the industry's 3.6% decline. Image Source: Zacks Investment Research In the reported quarter, total revenues were generated entirely by its only marketed drug, Arikayce, which is approved for treating refractory mycobacterium avium complex (MAC) lung disease in adults with limited or no alternative treatment option. The rise in Arikayce sales was driven by continued growth in demand across all marketed regions. Sales of the drug increased 13% to $66.9 million in the United States, while that in Japan rose 31% to $21.0 million. Sales in Europe
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR Newswire
- Insmed To Present at November 2024 Investor ConferencesPR Newswire
- Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $105.00 price target on the stock, up previously from $100.00.MarketBeat
- Do You Believe in the Growth Potential of Insmed (INSM)? [Yahoo! Finance]Yahoo! Finance
- Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.MarketBeat
INSM
Earnings
- 10/31/24 - Miss
INSM
Sec Filings
- 10/31/24 - Form 10-Q
- 10/31/24 - Form 8-K
- 9/16/24 - Form 4
- INSM's page on the SEC website